What is evolocumab (Repatha) used for in adults with established atherosclerotic cardiovascular disease?

Evolocumab (Repatha) reduces cardiovascular risk by lowering LDL-C in adults with established atherosclerotic cardiovascular disease, alongside correction of other risk factors and maximum-tolerated statin therapy, with or without other lipid-lowering treatments, or alone or with other lipid-lowering treatments if statins are not tolerated or contraindicated.